aap Implantate AG

Earnings Release • Oct 1, 2012

News Details

Ad-hoc | 1 October 2012 16:04

aap Implantate AG: 25% revenue growth to EUR 8.6 million in the third quarter of 2012; Total sales in the first nine months of 2012 increase to EUR 27.5 million (+31%)

aap Implantate AG / Key word(s): Quarter Results/Preliminary Results

01.10.2012 16:04

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Preliminary figures indicate that aap Implantate AG (XETRA: AAQ.DE), a
global medical device company focused on innovative trauma products and
biomaterials for the orthopaedic market, achieved sales in the third
quarter of 2012 of EUR 8.6 million, a 25% increase on the previous year's
figure of EUR 6.9 million. Therefore, total sales in the first nine months
of the financial year 2012 increase by 31% to EUR 27.5 million (previous
year: EUR 21 million).

The sales growth in the third quarter 2012 was mainly driven by increased
sales with our innovative LOQTEQ(R) product family as well by a sales
increase in the Biomaterials business. In the third quarter of 2012 we
signed distribution agreements for our LOQTEQ(R) product line in important
countries such as Spain, Portugal, Turkey, Egypt, Mexico, Brazil and
Argentina.

aap plans to publish the full Q3 2012 report on November 12, 2012.

This release contains forward-looking statements based on current
experience, estimates and projections of the management board and currently
available information. They are not guarantees of future performance.
Various known and unknown risks, uncertainties and other factors could lead
to material differences between the actual future results, financial
situation, development or performance of the company and the estimates
given here. Many factors could cause the actual results, performance or
achievements of aap to be materially different from those that may be
expressed or implied by such statements. These factors include those
discussed in aap's public reports. Forward-looking statements therefore
speak only as of the date they are made. aap does not assume any obligation
to update the forward-looking statements contained in this release or to
conform them to future events or developments.
______________________________________________________
aap Implantate AG (ISIN DE0005066609)
- Prime Standard/Regulated Market - All German stock markets -

aap is a global medical device company headquartered in Berlin, Germany
that develops, manufactures and markets innovative biomaterials and
implants that are used in orthopedic procedures. The Company's products,
which include a full line of plating systems, cannulated screws and bone
cement products, are primarily used in the orthopedic specialty areas of
trauma and spine repair. The Company's products are sold through its direct
sales force, distribution partners and license agreements with OEM
partners. aap's stock is listed in the Prime Standard segment of the
Frankfurt Stock Exchange. For more information, please visit www.aap.de.
For inquiries please contact:
aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099
Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, m.heydrich@aap.de

01.10.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE0005066609
WKN: 506660
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart

End of Announcement DGAP News-Service

---